Vivos Inc. announced new data demonstrating the exceptional precision of its proprietary Precision Radionuclide Therapy, encompassing RadioGel for human therapies and IsoPet for veterinary applications. The company highlighted the high therapeutic ratio achieved in clinical studies, which was a key factor in RadioGel receiving FDA Breakthrough Device designation. This ratio, initially validated by health physics calculations, is now supported by animal health division data and human trial data.
In veterinary applications, Dr. Ben Buchanan successfully treated Ocular Squamous Cell Carcinoma in multiple horses, including injections directly into eyelid tumors and onto the cornea, with no damage to surrounding eye tissue or reported adverse effects. This demonstrates the therapy's ability to target sensitive areas effectively.
In the international human trial, cancerous lymph nodes located near critical structures like the trachea and carotid artery were treated effectively. At 90 days post-treatment, these tumors were undetectable by imaging, with no measurable damage or reported adverse effects observed in surrounding critical structures. This unique capability for treating challenging tumors has the potential to significantly expand the addressable market for Vivos's therapies.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.